1.
Establishment of a central haemophilia organisation in each country with supporting local group.
2.
National Haemophilia patient registries.
3.
A network of multidisciplinary comprehensive care centres and complementary haemophilia treatment centres.
4.
Partnership of health care professionals and patients in the delivery of haemophilia care.
5.
Safe and effective concentrates at optimum treatment levels.
6.
Home treatment and delivery.
7.
Prophylaxis.
8.
Specialist services and emergency care.
9.
Management of inhibitors.
10. Encouragement of education and research.
In 2010, a report on the Optimal Use of Blood and Blood products was published by the European division for the quality of medicine. 2 Among the specific recommendations made in relation to treatment of Haemophilia was that at national level the minimum acceptable level of FVIII use should be at least 2 IU per capita.
In 2009, we carried out a survey to determine the extent to which these requirements of haemophilia care already applied in the various countries within Europe. 3 A total of 19 countries responded. A further survey was carried out in 2012 and a total of 35 countries responded.
METHodS
Between February and July 2012, a questionnaire was developed and sent out to the 43 national haemophilia patient organisations affiliated to the EHC in all European countries. Responses were received from 35 countries. The national haemophilia organisations that responded were not asked to specify the sources of their data, but typically they would have consulted clinicians and the national registry, where one exists, in addition to their own records. It was not practical to 130 ascertain the precise sources of the information used by each national member organisation in providing data for this survey, however, all information provided was provided with the best available knowledge of the organisations.
A greater degree of accuracy may be expected from countries where there is a national register and where this information is available to the national member organisation. Organisations were requested to supply factor usage for the calendar year 2011, however, due to the lack of access to this information in some countries this information may be older than this but the best available to the organisation when the survey was completed. The questionnaire was based on examining the extent to which the European principles of care and the EDQM recommendations on optimal use reflect the reality of haemophilia care in these countries. The questionnaire consisted of 35 questions covering aspects of the 10 basic requirements for haemophilia care. The countries that responded ( part II -CHAPTER 8 academic organisation is involved and in 6 countries the national haemophilia patient organisation is involved. Eight countries have more than one organisation involved in the registry. In 18 countries there is a treatment centre which is designated as the National treatment centre with responsibility for coordination including the national register. A total of 13 countries have a system for the classification of their Haemophilia treatment centres. In relation to partnership in the delivery of haemophilia care, countries were asked who has a significant role in relation to national decision making on haemophilia care and also who has a role in the choice of treatment products for haemophilia ( Fig. 8.1 ). In relation to the decision making on haemophilia care nationally, six countries (Azerbaijan, Belarus, France, Greece, Ireland and Ukraine) stated that the government played a significant role. A total of 27 countries stated that the health ministry played a significant role (including the 6 countries that stated that the Government played a significant role), 3 countries (Finland, France, and Turkey) stated that the Ministry of Social affairs played a significant role, 4 countries (France, Slovenia, Switzerland and the UK) stated that patients played a significant role, whereas 23 countries stated that the national haemophilia patient organisation played a significant role (including these 4) and 23 countries stated that clinicians played a significant role. In the majority of countries, the clinicians, the health ministry and the patient organisation were those that played a significant role in the decision making with 14 countries stating that all 3 played a significant role, 3 countries stating that the Health Ministry and clinicians played a significant role and 3 countries stating that the clinicians and patient organisation played a significant role.
factor replacement therapy
In relation to choice of haemophilia treatment products ( Fig. 8.1 ), 18 countries stated that the health ministry were involved with the choice, 4 countries (Italy, Slovenia, Turkey and Ukraine) stated that the regional government were involved. Regional Government was reported to be involved by Sweden in the previous survey, but this has changed and they now report the Health Ministry as being involved. Hospitals were involved in 11 countries, patients in 6 countries, the national haemophilia patient organisation in 6 countries (Ireland, Poland, Russia, Serbia, Slovakia and UK), clinicians in 16 countries and a national procurement committee in 7 countries (Belarus, Finland, Ireland, Italy, Serbia, Slovakia and UK). In the case of Ireland, the patient organisation is fully involved in the decision making as they have a formal role in the national procurement committee for factor concentrates. A total of 17 countries have a national tender for the procurement of factor concentrates. The survey revealed enormous variation in relation to the availability of factor concentrates in the European countries surveyed ( Fig. 8 If we use GDP per capita as a crude measure of economic strength, the countries that underperform are Switzerland, Spain and at lower factor VIII usage Romania and Armenia ( Fig. 8.2 ).
Hungary continues to perform very impressively in relation to their GDP, but since the last survey in 2009, the most marked increase in the FVIII use can be seen in Lithuania, Russia, Czech Republic, Bulgaria and Slovakia. Ireland and the UK show significant increase in FVIII use despite their economic difficulties. If we look at the changes in the 19 countries that responded to the previous survey in 2009, GDP has decreased in 1 country (Ireland), health expenditure has decreased in 11 countries ranging from 1% (Germany) to 10% (Ireland). Despite this decrease in health spending, FVIII use decreased in only 2 countries. One of these (Latvia) had a decrease in health spending. FVIII use increased in 15 countries ranging from a 1.4% increase (Germany) to 73% increase 
home treatment and prophylaXIs
Home treatment is available in 32 of the 35 countries surveyed and is delivered directly to the patients home in 13 of the countries (Table 8. 3). Home treatment is not available in Albania, Armenia and Romania. It is available to 75-100% of people with Haemophilia in 19 countries, available to 50-75% in 5 countries and available to 10-50% in further 5 countries. The three countries where home treatment is not available each consume less than 1 IU per capita of factor VIII, although Ukraine, which also consumes less than 1 IU per capita, reports that they do have availability of home treatment but to less than 10% of people with Haemophilia.
Prophylaxis is theoretically available to all persons with haemophilia in 18 countries, (Table   8 .3) available for some people in further 12 countries and available to children in 4 countries.
Prophylaxis is not available in the 3 countries where home treatment is not available Prophylaxis is available to children with severe haemophilia in 18 countries to the extent that 75-100% of children avail prophylaxis. Prophylaxis is available to 50-75% of children with haemophilia in a further 6 countries. Prophylaxis is available for 1-25% of children in 7 countries.
In Sweden, 76-100% of adults are on prophylaxis. In 4 countries, 51-75% of adults are on prophylaxis. In 10 countries, 26-50% of adults are on prophylaxis. In 12 countries, up to 25%of adults are on prophylaxis. Seven countries report no adults having availability of prophylaxis, whereas UK does not report the percentage of adults on prophylaxis (Table 8. 3).
Immune tolerance for patIents wIth InhIBItors.
Eight countries reported that immune-tolerance therapy is not available at all. Immune tolerance is available for the majority of patients in 18 countries and to some patients in further 8 countries and availability is not reported in 1 country ( There was no access to infectious diseases specialists in 2 countries with 7 countries reporting sporadic access, 12 countries reporting sporadic access to physiotherapy and 9 reporting sporadic access to dentistry. Genetics was not available in 3 countries and sporadically available in 12. Social and psychosocial support was not available in 6 countries and sporadically available in 14 countries. Pain management was not available in 6 countries and sporadically available in 13 countries. Clearly there is a major divergence in relation to access to the different specialities, which are either a core part of or augment the comprehensive care team.
part II -CHAPTER 8 139 The survey revealed significant variation in relation to the organisation of haemophilia care and availability of factor concentrates in the European countries surveyed. The impact and utility of the previous survey was, in the opinion of the authors, a major reason for the greatly increased number of countries responding to the survey on this occasion. Political support will be required to continue to develop haemophilia care in Europe and it is gratifying that the results of this survey were the subject of a roundtable conference organised by the European Haemophilia Consortium at the European Parliament in October 2012.
If we compare the results in the 19 countries that completed the survey in both 2009 and 2012, some interesting results are evident. The impact of the economic crisis is seen by the fact that the GDP has decreased in 1 country (Ireland) and health expenditure has decreased in 11 countries.
In 2 countries (Ireland and Bulgaria) FVIII use per capita has increased despite decreased health expenditure. In Ireland, FVIII use increased from 6.75 to 8.09 IU per capita (20% increase). This increase coincided with a fall in GDP of 3% and a fall in health expenditure of 10%. The reason for the increase in factor use is primarily due to the work of the Haemophilia Product Selection and
Monitoring Advisory Board that carry out the national tenders. A lower health budget was managed by this group by achieving significantly lower prices for FVIII by competitive national tender using rigorous scoring criteria and also by elimination of handling and distribution fees resulting from a change in contract holder.6 This allowed the purchase of greater amounts of factor concentrate without affecting the quality of the concentrates purchased and allowed targets to be met for lower national health expenditure in this area. In Bulgaria, health spending decreased by 6%, but FVIII use per capita increased from 1.62 to 2.14. This increase in the use of FVIII was partially due to the advocacy efforts of the national Haemophilia patient organisation and their work in bringing together key stakeholders (personal communication J. Nedevski, Bulgarian Haemophilia Society).
In Lithuania, FVIII use increased from 1.82 to 3.37 IU per capita. Although this increase is very significant, it must be remembered that the initial level FVIII use was relatively low. Individual im- couraging that the general trend towards lower health expenditure has not been mirrored by lower availability of replacement therapy or access to prophylaxis or home treatment in the majority of countries. We attribute this to the strong and well-established profile of haemophilia treatment in many countries and the active work of the patient organisations and their collaboration with the haemophilia clinicians. It is surprising that only 17 of the 35 countries have a national tender for procurement of factor concentrates. In countries where this is the case and where the results are known to the authors, this mechanism, providing that the key clinicians and national patient organisation are involved, has led in several countries to very significant reductions in the cost of factor concentrates and therefore has contributed to maintaining or even increasing (as in the cases of Ireland and the UK) the national use of factor concentrates.
If we look at the availability of factor replacement therapy separately in EU and non-EU coun- access to genetics and psychological support and the Czech Republic has improved access to physiotherapy and psychological support. There has been an improvement with regard to genetic services in the UK as well as access to dental care. There were problems in the past with dental part II -CHAPTER 8 145 care, related to concern about vCJD.7 Slovakia has reported improved access to pain management and Sweden to genetics.
The survey results can and should be used by national member organisations in collaboration with their haemophilia clinicians to advocate with their government for improving care in their specific country where deficiencies have been identified. Countries where the FVIII per capita use is significantly out of step with their GDP per capita could use this data to advocate for increased availability of treatment with their government. In using this data for advocacy purposes, comparisons can be made by a particular country with the overall findings (e.g. Latvia uses 1.70 IU per capita of FVIII compared to an EU mean of 5.4 IU per capita) and the European Principles of Care and EDQM Guidelines can be referenced. In some cases, it may be more advantageous with the government to compare the results with neighbouring countries with similar economic indicators (for the above example, Latvia could be compared with Lithuania where FVIII per capita use is 3.37 IU per capita, use has increased very significantly since 2009 and the decrease in health expenditure in that time at 7% was greater than the decrease in Latvia which was 5%). Similarly, if the national patient organisation in the Czech Republic was advocating for a national tender, they could refer the fact that 17 of the 35 European countries surveyed have such a system in place or it may be more advantageous to refer the fact that their neighbour, Slovakia, has such a tender in place. Health policy is not the responsibility of the EU -it remains a national responsibility. There is no real prospect of harmonization of availability of treatment and care in the EU based on legislation, but consensus guidelines such as the European Principles of Care or EDQM Guidelines can and do constitute powerful advocacy tools in arguing for improved care. This applies, not only to EU member states, but to candidate countries that aspire to EU membership.
They can also be applied to non-EU member states as recommendations agreed by key clinician's and patient organisation representatives from many countries and therefore are as close as we may get to agreed standards of care in a European context.
The results of this survey are broadly encouraging as the decrease in health expenditure in many countries has not been matched by a corresponding decrease in access to haemophilia treatment or care. We look forward to commenting on the changes in these 35 countries when this survey is repeated in 2014.
